## IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP2003/010890

International Filing Date : October 1,2003

Priority Date(s) Claimed : October 25, 2002

Applicant(s) (DO/EO/US) : Herve DUMAS et al.

Title: N-BENZODIOXOLYL, N-BENZODIOXANYL AND N-BENZODIOXEPINYL ARYLCARBOXAMIDE DERIVATIVES WHICH CAN BE USED FOR THE TREATMENT OF DYSLIPIDAEMIA, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

## Timing and Fees

Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:				
	within three months of the filing date of a national application other than a CPA under § 1.53(d);			
	within three months of the actual filing date of the national phase of a PCT application; OR			
$\boxtimes$	before the mailing of a first substantive office action (including after filing of an RCE).			
	37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods ted in 37 C.F.R. § 1.97(b), but before the mailing date of:			
	a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and			
	disclos			

		is acco	empanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a r	notice of allowance under 37 C.F.R. § 1.311;
	AND i	s filed o	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).
Statem	ents Ur	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited ]	Materia	<u>ls</u>	
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
	$\boxtimes$	_	s of materials listed but not attached were cited in an international search dated January 8, 2004.
		Not re	quired by 37 CFR § 1.98.
		Copie	s of the materials listed are attached (except for the foregoing).

Non-English	Language References				
$\boxtimes$	An English-language search report or equivalent paper from a foreign paten office is provided indicating the relevance of the cited reference(s).				
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:				
	<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> <li>A = document defining the general state of the art</li> <li>O = non-written disclosure</li> <li>P = intercalated document</li> <li>T = document cited to understand the theory or principle underlying the invention</li> <li>E = patent document which has the benefit of a date earlier than the filing date</li> </ul>				
	and which was published only on or after this filing date  D = cited in the application  L = cited for another reason  & = publication of member of same patent family				
	Translation of other relevant information on foreign search report  [insert necessary translation here]				
Other Inform	ation				
	ees Due (If Any):  ck for \$ covering the fee identified above is attached.				

Please charge to Deposit Account No. 13-3402 \$\_\_\_\_\_ for the fee identified above.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza l
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3001

Date: April 25, 2005

AJZ/apl

K:\Merck\3001\Information Disclosure Statement.doc





Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)\_

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number Unassigned INFORMATION DISCLOSURE April 25, 2005 Filing Date STATEMENT BY APPLICANT First Named Inventor Herve DUMAS et al. Group Art Unit Unassigned (use as many sheets as necessary) **Examiner Name** Unassigned **MERCK-3001** of Attorney Docket Number Sheet

		U.S. Patent Document				
Examiner Initials *	Cite No.1	Number	Kind Code <sup>2</sup> ( <i>if known</i> )	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document  MM-DD-YYYY	
	1	3865832			February 11, 1975	
-	2	2002040014			April 4, 2002	
	3	5037825			August 6, 1991	
	4	2001041814			November 15, 2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Foreign Patent Docur	nent Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ•
	5	wo	0166553		Metabasis Therapeutics	September 13, 2001		Equv to cite 2
	6	EP	0350846		Hoffman La Roche	January 17, 1990		Equv to cite 3
	7	EP	0919542		Nihon Nohyaku	June 2, 1999		Equv to cite 4
	8	wo	0228835		Fujisawa	April 11, 2002		
	9	FR	2181708		Philps	December 7, 1973		Equv to cite 1

Examiner Signature	Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.